The PRESTA Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis study, a randomized, double-blind, two-dose plaque psoriasis, examined the efficacy of etanercept treatment in patients with moderate-to-severe plaque psoriasis and PsA and the main results have been presented previously.
This analysis examined employment status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population. All participants then received open-label etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization.
A pharmacoeconomic questionnaire was administered at baseline, week 12 and week 24 of treatment. The questionnaire included employment status and changing job responsibilities and sick time taken due to psoriasis or PsA. The statistical methods included analysis of covariance, t-test, Fisher's exact test and McNemar's test.
Last-observation-carried-forward imputation was used for missing data. The number of monthly sick days also decreased from baseline to week 24 2. No significant differences between the treatment groups were observed for plaque psoriasis economic endpoint at any time point.
Effective treatment of psoriasis and PsA may reduce missed work days.